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Abstract
Objective
To determine the effects of the disease-modifying therapies, glatiramer acetate (GA) and
dimethyl fumarate (DMF), on the gut microbiota in patients with MS.
Methods
Participants with relapsing MS who were either treatment-naive or treated with GA or DMF
were recruited. Peripheral blood mononuclear cells were immunophenotyped. Bacterial DNA
was extracted from stool, and amplicons targeting the V4 region of the bacterial/archaeal 16S
rRNA gene were sequenced (Illumina MiSeq). Raw reads were clustered into Operational
Taxonomic Units using the GreenGenes database. Differential abundance analysis was per-
formed using linear discriminant analysis effect size. Phylogenetic investigation of communities
by reconstruction of unobserved states was used to investigate changes to functional pathways
resulting from differential taxon abundance.
Results
One hundred sixty-eight participants were included (treatment-naive n = 75, DMF n = 33, and
GA n = 60). Disease-modifying therapies were associated with changes in the fecal microbiota
composition. Both therapies were associated with decreased relative abundance of the Lach-
nospiraceae and Veillonellaceae families. In addition, DMFwas associated with decreased relative
abundance of the phyla Firmicutes and Fusobacteria and the order Clostridiales and an increase
in the phylum Bacteroidetes. Despite the different changes in bacterial taxa, there was an
overlap between functional pathways affected by both therapies.
Interpretation
Administration of GA or DMF is associated with differences in gut microbial composition in
patients with MS. Because those changes affect critical metabolic pathways, we hypothesize
that our findings may highlight mechanisms of pathophysiology and potential therapeutic
intervention requiring further investigation.
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MS is believed to result from interactions between underlying
genetic predisposition and environmental exposures.1,2 En-
vironmental risk factors, including vitamin D levelse1 (links.
lww.com/NXI/A86), viral exposures,e2 smoking,e3 and obe-
sity,e4,e5 are related to MS onset and disease course. However,
most of the environmental risk factors in MS remain un-
explained. In consideration of additional potential mediators,
the gut is a natural site of investigation, given that it is a major
locus of environmental interaction and home to a large por-
tion of the human immune system. In addition, immunologic
development and patterning, dysregulated in MS and other
autoimmune diseases, is heavily influenced by resident com-
mensal microbes, the microbiota. Gut microbial composition
is shaped by both genetics and environmental exposures that
begin in utero, providing a potential pathogenic link between
these factors and autoimmune diseases such as MS. Studies of
experimental allergic encephalomyelitis (EAE) in mice have
demonstrated reduced disease severity with administration of
oral antibiotics3 and established that the presence of com-
mensal flora is required for EAE induction.4
Several groups have begun to study the gut microbiota in
patients with MS to identify a potential disease-associated
signature.5–9 However, initial studies were limited by small
numbers of participants and potentially confounded by the
effects of disease-modifying therapies (DMTs). Separating
changes in microbial composition related to MS disease state
from changes induced by DMTs is crucial to further un-
derstand the role of gut microbiota in MS. We recently
reported structural and functional changes in gut microbiota in
untreated patients with MS compared with healthy controls10;
in the current study, we began to examine the effects of DMT.
Therapy-induced changes in microbial composition may
contribute toward efficacy by favoring microbes with anti-
inflammatory properties, for example by influencing T-cell
differentiation toward regulatory phenotypes or promoting
the production of regulatory cytokines. This could manifest
either as a “reversal” of observed differences in baseline gut
microbiota associated with the MS disease state or in un-
related changes that nonetheless promote immune tolerance
over inflammation in MS. Some changes may be neutral and
still others may be detrimental, contributing to incomplete
efficacy. Changes to individual taxa may be less important
than the overall reshaping of the microbial community.
This cross-sectional study was designed to define the effects of
2 commonly prescribed DMTs on gut microbial composition
in patients with MS. Glatiramer acetate (GA) is administered
by subcutaneous injection. It is a random copolymer of ala-
nine, lysine, glutamic acid, and tyrosine with widespread im-
munomodulatory effects including effects on antigen
presentation and polarization of naive T cells away from TH1
and TH17 and toward TH2 and regulatory phenotypes with
accompanying changes in cytokine profilese6 (links.lww.com/
NXI/A86). Efficacy in MS was established by several clinical
trialse7–e9 and it has been U.S. Food and Drug Administration
(FDA) approved for the treatment of MS since 1996. Di-
methyl fumarate (DMF) is an orally administered fumaric
acid ester. Immunological effects relevant to MS include
antiproliferative effects, inhibition of the NF-KB pathway,
promotion of the heme oxygenase pathway, and anti-
inflammatory effects related to T-cell differentiation and cy-
tokine production.e10 Efficacy was established by 2 large
clinical trials,e11,e12 and U.S. FDA approval was granted for
MS in 2013.
In this study, we demonstrate that these 2 immunomodula-
tory therapies distinctly alter gut microbial composition in
patients with MS.
Methods
Participants were recruited at the Corinne Dickinson Gold-
smith Center for Multiple Sclerosis at Mount Sinai (New
York, NY) between August 2013 and December 2015 and at
the University of California San Francisco Multiple Sclerosis
Center (San Francisco, CA) between July 2013 and Sep-
tember 2016 as part of the MS Microbiome Consortium.
Potential participants aged 18–65 years were approached by
MS Center clinicians during clinical visits. Patients with MS
were eligible to participate if they met the McDonald 2010
criteria for relapsing-remitting MS or qualified as having
clinically isolated syndrome along with abnormal brain MRI
and were either naive to MS DMT or stable on GA or DMF
for at least 3 months. Participants could not have taken
antibiotics within 3 months or high-dose corticosteroids
within 1 month of enrollment. Additional exclusions were
a diagnosis of diabetes or inflammatory bowel disease, recent
gastroenteritis, and treatment with an immunosuppressant
medication for any condition in the 3 months preceding
enrollment.
Clinical data
Clinical details including demographic information, detailed
MS disease history, medical history, and height and weight
Glossary
DMF = dimethyl fumarate; DMT = disease-modifying therapy; EAE = experimental allergic encephalomyelitis; FDA = Food
and Drug Administration; GA = glatiramer acetate; IFN = interferon; LEfSe = linear discriminant analysis effect size; LDA =
linear discriminant analysis; OTU = operational taxonomic unit; PICRUSt = phylogenetic investigation of communities by
reconstruction of unobserved states.
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were recorded. The Expanded Disability Status Scale was
completed by the treating MS clinician or abstracted from the
electronic medical record by one of the study investigators
(I.K.S. and R.B.). Statistics were performed using SPSS 23.
Microbiota
Sample collection
Research coordinators reviewed detailed instructions regarding
stool collection with all participants and provided them stool
kits to be completed at home. Care was taken to match the kits
and instructions at both institutions using a dry swab techni-
que (BD #220135; Becton, Dickinson and Company, Franklin
Lakes, NJ). Participants were instructed to collect stool samples
using the first bowel movement of the day on 2 separate days,
preferably 2 days within the same week. They were then
instructed to place each completed kit between 2 freezer packs
inside a thermal envelope and ship immediately or keep in their
home freezer if there was to be a short delay in shipping. A
prepaid return shipping label for overnight shipping was pro-
vided tominimize transit time. Participants were also instructed
to send samples only in the early part of the week to avoid
samples arriving over the weekend. On receipt, samples were
immediately placed at −80°C until bacterial DNA extraction.
16S rRNA amplicon sequencing and data analysis
The workflow for microbiota sequencing and analysis is
outlined in figure 1. DNA was extracted from samples using
the PowerSoil DNA Isolation Kit (MoBio #12888) according
to the manufacturer’s instructions. For each sample, PCR
targeting the V4 region of the bacterial/archaeal 16S rRNA
gene was completed in triplicate using the 515/806 primer
pair, and amplicons were sequenced using Illumina MiSeq
(150 bp paired-end) sequencing primers, and procedures
were described in the Earth Microbiome Project standard
protocol.11
Raw reads were clustered into Operational Taxonomic Units
(OTUs) using closed-reference SortMeRNA12 method at 97%
identity based on the GreenGenes database v13.8 using Quan-
titative Insights Into Microbial Ecology (QIIME) v1.9.13 Tax-
onomy was assigned to the retained OTUs based on the
GreenGenes reference sequence, and the GreenGenes tree was
used for all downstream phylogenetic community comparisons.
Samples with less than 10,000 sequences per sample were fil-
tered out. OTUs were filtered to retain only OTUs present in at
least 5% of the samples and containing at least 100 reads. Several
very rare (relative abundance <5 × 10−5) OTUs including
OTUs 4295564 (k__Bacteria; p__[Thermi]; c__Deinococci;
Figure 1 Flow chart explaining the bioinformatic pipeline and statistical methods (see Methods for details)
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o__Thermales; f__Thermaceae; g__Thermus; s__), 112194
(k__Bacteria; p__Proteobacteria; c__Alphaproteobacteria;
o__Rickettsiales; f__Rickettsiaceae; g__Rickettsia; s__), and
4319519 (k__Bacteria; p__Spirochaetes; c__Spirochaetes;
o__[Borreliales]; f__[Borreliaceae]; g__Borrelia; s__) were
identified as potential contaminants and were removed. Sam-
ples collected from the same participant within 1 week were
combined to 1 sample by averaging the OTU tables.
After filtering, samples were rarefied to 10,000 sequences per
sample, and alpha and beta diversities were computed using
QIIME v1.9. Unweighted UniFrac14 was used as the distance
metric to perform principal coordinate analysis and to generate
the corresponding plots. Alpha-diversity differences across the
3 treatment groupswere tested by the non–parametric Kruskal-
Wallis rank test. Beta diversity differences were assessed by
comparing the within-group and between-group unweighted
UniFrac distances using a non–parametric 2-sample t-test
based on 1,000 Monte Carlo permutations, followed by
a Bonferroni correction for multiple testing. Differential
abundance analysis was performed using linear discriminant
analysis effect size (LEfSe).15 Briefly, the non–parametric
Kruskal-Wallis rank test was first applied to detect differentially
abundant taxa. Significant taxa (p < 0.05) were then used to
build a linear discriminant analysis (LDA) model, which esti-
mated the effect size associated with a treatment group. p< 0.05
and LDA score >2 were used as the criteria to determine dif-
ferentially changed taxa after treatment compared with samples
from those who were treatment-naive.
To infer metagenomic functions (and predict metabolic
functions from the predicted gene content) of the bacteria
significantly altered by DMTs, the software package phylo-
genetic investigation of communities by reconstruction of
unobserved states (PICRUSt) v1.1.116 was applied to all
OTUs (2,191 OTUs) after quality filtering as described
above, following the recommended pipeline of normalizing
OTUs by copy number (to account for copy number differ-
ences of the 16S rRNA gene among taxa), predicting func-
tions using the Kyoto Encyclopedia of Genes and Genomes
orthologs, and assembling predicted Kyoto Encyclopedia of
Genes and Genomes orthologs into functional pathways.
Differentially changed metabolomic pathways between the
treated and naive groups were identified using the non–
parametric Kruskal-Wallis rank test, followed by the
Benjamini-Hochberg correction for multiple testing with
a false discovery rate ≤15%, reflecting the exploratory nature
of this piece of the study.
Immunophenotyping
Whole blood was collected for immunophenotyping (only at
Mount Sinai because of the requirement for fresh samples)
and immediately processed byMount Sinai’s Human Immune
Monitoring Core. Specimens were stained with a pre-
optimized T-cell antibody cocktail and acquired within 3
hours using a BD LSR Fortessa (BD, San Jose, CA). A min-
imum of 500,000 events were recorded from each sample to
accurately assess minor cell populations. Compensation was
performed with unstained cells and BD compensation beads.
FlowJo 9.4 software (Treestar Inc, San Carlos, CA) was used
for postacquisition analysis. Statistical analysis was performed
using unpaired 2 tailed t-test (GraphPad Software, La
Jolla, CA).
Standard protocol approvals, registrations,
and patient consents
The research was approved by the Institutional Review
Boards at Mount Sinai and UCSF, and written informed
consent was obtained from all participants.
Data availability statement
Anonymized data are available and will be shared on request
from any qualified investigator.
Results
The study enrolled a total of 186 participants who met the
inclusion criteria. Of these, 168 (90.3%) had at least 2 samples
whose DNA passed quality control measures and were ulti-
mately included. This includes 75 participants who were
treatment-naive, 33 treated with DMF, and 60 treated with
GA as outlined in figure 1. Immunophenotyping data were
available only for a subset of the participants recruited at
Mount Sinai (n = 30 naive, n = 26 DMF, and n = 12 GA).
Clinical characteristics of study participants, broken down by
treatment group, are outlined in table 1 (microbiota) and
table e-1 (links.lww.com/NXI/A89, immunophenotyping).
Immunophenotyping profiles validated the
expected effects of DMF and GA
Peripheral blood mononuclear cells were collected from 68
participants recruited at Mount Sinai (treatment-naive n = 30,
DMF n = 26, and GA n = 12) and analyzed by FACS to
identify CD3, CD4, and CD8 populations. The surface
markers CCR4 and CCR6 were used to further classify CD4
T cells as Th17 (CCR4+CCR6+)e13 (links.lww.com/NXI/
A86) or Th2 (CCR4+CCR6−).e14
DMF treatment was associated with reduced percentage of
CD3, CD4, and CD8 T cells as previously describede15 (links.
lww.com/NXI/A86). DMF treatment was also associated
with a reduced percentage of CCR4+ CCR6+ T cells (t-test, p
< 0.0001), as well as a milder reduction of CCR4+CCR6−
T cells (t-test, p = 0.02). Treatment with GA did not have any
effect on total CD3 or CD4 percentage but was associated
with a reduced percentage of CCR4+ CCR6+ T cells com-
pared with treatment-naive patients (t-test, p = 0.02), which
was not significantly different from the effect of DMF on those
cells (t-test, p = 0.2) (figure e-1, links.lww.com/NXI/A87).
Administration of DMF or GA results in distinct
alterations to gut microbial composition in
patients with MS
16S amplicon sequencing was performed on the Illumina
MiSeq platform to assess changes in the fecal microbiome of
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patients with MS after different treatments. In total,
49,679,344 raw reads passed the quality filtering in QIIME
and were clustered into OTUs based on the GreenGenes
database at a 97% sequence identity. We further applied
stringent filters to remove samples with low sequencing reads
and rare taxa (see Methods for detail) and then combined
multiple collections within a short time interval from the same
participant to counteract temporal variations (figure 1). This
resulted in 8,542,763 high-quality reads (on average 49,628 ±
31,746 reads per participant) mapping to 2,191 unique
OTUs. At the phylum level, the microbiota of all patients with
MS was comprised predominately of Firmicutes (45.9%) and
Bacteroidetes (41.0%) and to a lesser extent of Proteobacteria
(8.7%), Actinobacteria (2.0%), and Verrucomicrobia (2.0%),
consistent with recent reports on microbiota profiles identi-
fied in patients with MS or healthy participants on a Western
diet5,6,17,18 (figure 2).
Because our sample collections were made at 2 geographically
distinct sites, we first established that there were no
community-level differences between the 2 sites (figure e-2,
links.lww.com/NXI/A88). Because there were more women
than men in our study and the proportion of women differed
by therapy, we also performed diversity analyses between
sexes. Although no alpha diversity differences were detected,
we detected small within-sex and between-sex beta diversity
differences (p = 0.01, effect size = 0.6%) that are not notice-
able on a principal coordinate analysis plot (figure e-2). As
shown in figure 2, administration of DMF orGA did not result
in overall changes to microbial community structure as
measured by alpha diversity (richness of taxa within samples
by observed_species or richness and evenness of taxa within
samples by chao1) or beta diversity (diversity between dif-
ferent samples by unweighted UniFrac. However, LEfSe
analysis identified 13 differentially abundant bacterial genera
in patients with MS on DMF and 14 differentially abundant
genera in patients on GA, as compared to those who were
treatment-naive (table 2). Of interest, GA led to a reduction in
the relative abundance of 7 genera and an increase of 7 genera,
whereas all the 13 genera affected by DMF treatment showed
decreased relative abundance (figure 3). Among the taxo-
nomic units decreased by DMF, the most dramatic effect was
mapped to the order Clostridiales (figure 4), thereby sug-
gesting potential importance of this taxon.
Inference of functional consequences of
alterations in gut microbial composition
induced by DMF and GA
PICRUSt was used to evaluate potential functional implica-
tions of these changes in gut microbial profiles.16 We noted
significant changes in 42 pathways in DMF-treated partic-
ipants (30 increased and 12 decreased) and in 63 pathways in
GA-treated participants (36 increased and 27 decreased).
Despite the different route of administration and the different
effect on bacterial taxa, there was an overlap of 17 pathways
between the 2 therapies. GA and DMF had a concordant
effect on 15 of those pathways, which included pathways af-
fecting vitamin, amino acid, energy, and xenobiotic metabo-
lism. More specifically, among the common concordant
pathways affected were retinol (vitamin A), methane, and
ethylbenzene metabolism, as well as valine, leucine, and iso-
leucine degradation (figure 5).
Discussion
Defining the effects of DMT on gut microbial composition is
critical for the inclusion of treated MS patients in microbiota
studies and interpretation of any findings. This has been
established in several other disease states, for example, in
separating effects of metformin from those of the type 2 di-
abetes disease statee16 (links.lww.com/NXI/A86). Many
other medications, from non–steroidal anti-inflammatory
drugse17 to proton pump inhibitors,e18 have been shown to
affect the gut microbiota, and in this study, we demonstrate
that MS therapies do as well. Although we acknowledge that
definitive effects are best established through longitudinal
studies of samples collected before and subsequent to the start
Table 1 Participants’ demographic and MS disease characteristics
Treatment-naive (N = 75) Glatiramer acetate (N = 60) Dimethyl fumarate (N = 33)
Age 38.1 ± 10.9 45.7 ± 10.3 42.5 ± 10.9
Female 47 (62.7%) 46 (76.7%) 18 (51.5%)
BMI 25.1 ± 5.3 25.0 ± 4.6 26.6 ± 5.5
Disease duration 4.2 ± 5.8 10.4 ± 7.1 10.2 ± 7.3
Treatment duration NA 5.1 ± 3.7 1.5 ± 0.59
EDSS
Median 2.0 1.5 1.0
Mean 1.8 ± 1.2 1.4 ± 1.1 1.1 ± 1.2
Abbreviation: BMI = body mass index.
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of DMT, cross-sectional studies allow for preliminary evalu-
ation of these ideas and generation of hypotheses for further
study.
The phylum Bacteroidetes was increased in relative abun-
dance in our DMF cohort compared with the treatment-naive
cohort. This difference was mainly driven by an increase in the
genus Bacteroides that narrowly missed statistical significance.
This result is interesting in the context of other studies that
have looked at this commensal group in MS and suggested
a potential protective effect. A small study in pediatric MS
showed relative depletion of Bacteroides compared with
healthy controls.8 From a mechanistic standpoint, oral
administration of purified polysaccharide A produced by
Bacteroides fragilis was shown to mitigate EAE in an IL-10-
dependent fashion.19 Lipid 654, a lipodipeptide generated by
several commensal Bacteroidetes species, reaches the sys-
temic circulation and is reduced in the serum of patients with
MS compared with healthy controls.20 In an adoptive transfer
model of EAE, low-level Lipid 654 was administered to induce
toll-like receptor 2 tolerance and was found to attenuate EAE
and decrease macrophage activation and TH17 cells in the
Figure 2 Overall community differences in the gut microbiota of treated or untreated patients with MS
(A and B) Rarefaction curves plotting alpha diversity indices (A: Observed_species; B: Chao1) vs the number of sequences for each treatment group. n.s.: not
statistically significant by the Kruskal-Wallis sum-rank test. (C) Principal coordinate plot based on the unweighted UniFrac distance metric. The percentage of
variability explained by the first 3 principal components was plotted. Each colored point represents a participant from one of the therapy groups (Naive, DMF,
or GA). (D) No obvious beta diversity differences were observed across groups as demonstrated by similar within-group and between-group distances. n.s.:
not statistically significant by a non–parametric 2-sample t-test based on 1,000 Monte Carlo permutations, followed by a Bonferroni correction for multiple
testing. (E)Mean relative abundance of prevalentmicrobes (>1% in any therapy group) at the phylum level. DMF =dimethyl fumarate; GA = glatiramer acetate;
k = kingdom; p = phylum.
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Table 2 Differentially abundant taxa
Differentially abundant taxa score
Mean relative abundance
FC: log2 (DMF/NA) log10.LDA. p ValueNaive DMF
Phylum
k__Bacteria.p__Fusobacteria 3.0E-04 1.2E-05 −4.6 2.6 9.91E-03
k__Bacteria.p__Cyanobacteria 1.8E-03 1.8E-04 −3.3 2.6 3.56E-02
k__Bacteria.p__Firmicutes 5.1E-01 3.8E-01 −0.4 4.7 1.25E-02
k__Bacteria.p__Bacteroidetes 4.1E-01 5.0E-01 0.3 4.7 4.58E-02
Class
k__Bacteria.p__Fusobacteria.c__Fusobacteria 3.0E-04 1.2E-05 −4.6 2.7 9.91E-03
k__Bacteria.p__Proteobacteria.c__Epsilonproteobacteria 4.1E-04 7.6E-05 −2.4 2.8 1.39E-02
k__Bacteria.p__Firmicutes.c__Clostridia 4.8E-01 3.6E-01 −0.4 4.7 1.81E-02
k__Bacteria.p__Bacteroidetes.c__Bacteroidia 4.1E-01 5.0E-01 0.3 4.7 4.58E-02
Order
k__Bacteria.p__Fusobacteria.c__Fusobacteriia.o__Fusobacteriales 3.0E-04 1.2E-05 −4.6 2.6 9.91E-03
k__Bacteria.p__Actinobacteria.c__Actinobacteria.o__
Actinomycetales
2.8E-03 2.9E-04 −3.2 3.4 4.26E-03
k__Bacteria.p__Proteobacteria.c__Epsilonproteobacteria.o__
Campylobacterales
4.1E-04 7.6E-05 −2.4 2.9 1.39E-02
k__Bacteria.p__Firmicutes.c__Clostridia.o__Clostridiales 4.8E-01 3.6E-01 −0.4 4.7 1.81E-02
k__Bacteria.p__Bacteroidetes.c__Bacteroidia.o__Bacteroidales 4.1E-01 5.0E-01 0.3 4.7 4.58E-02
Family
k__Bacteria.p__Fusobacteria.c__Fusobacteriia.o__
Fusobacteriales.f__Fusobacteriaceae
2.96E-04 1.21E-05 −4.6 2.6 9.91E-03
k__Bacteria.p__Firmicutes.c__Clostridia.o__Clostridiales.f__
[Tissierellaceae]
1.28E-02 9.66E-04 −3.7 3.9 4.07E-03
k__Bacteria.p__Actinobacteria.c__Actinobacteria.o__
Actinomycetales.f__Corynebacteriaceae
2.19E-03 2.16E-04 −3.3 3.3 3.07E-02
k__Bacteria.p__Actinobacteria.c__Actinobacteria.o__
Actinomycetales.f__Actinomycetaceae
5.86E-04 7.47E-05 −3.0 3.1 3.26E-02
k__Bacteria.p__Actinobacteria.c__Actinobacteria.o__
Actinomycetales.f__Micrococcaceae
2.38E-05 4.30E-06 −2.5 2.7 6.91E-04
k__Bacteria.p__Proteobacteria.c__Epsilonproteobacteria.o__
Campylobacterales.f__Campylobacteraceae
4.14E-04 7.59E-05 −2.4 2.9 1.39E-02
k__Bacteria.p__Firmicutes.c__Clostridia.o__Clostridiales.f__
Veillonellaceae
1.72E-02 9.77E-03 −0.8 3.4 4.36E-02
k__Bacteria.p__Firmicutes.c__Clostridia.o__Clostridiales.f__
Lachnospiraceae
1.93E-01 1.54E-01 −0.3 4.3 1.37E-02
k__Bacteria.p__Firmicutes.c__Bacilli.o__Bacillales.f__
Planococcaceae
2.02E-06 0 NA 3.4 3.88E-02
Genus
k__Bacteria.p__Actinobacteria.c__Actinobacteria.o__
Actinomycetales.f__Actinomycetaceae.g__Varibaculum
3.46E-04 1.25E-05 −4.8 2.3 1.89E-03
k__Bacteria.p__Firmicutes.c__Clostridia.o__Clostridiales.f__
[Tissierellaceae].g__WAL_1855D
3.16E-03 1.17E-04 −4.8 3.3 5.91E-03
k__Bacteria.p__Fusobacteria.c__Fusobacteriia.o__
Fusobacteriales.f__Fusobacteriaceae.g__Fusobacterium
2.96E-04 1.21E-05 −4.6 2.7 9.91E-03
Continued
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CNS.21 Our results suggest that the observed effects of DMF
on gut microbiota might be relevant to its anti-inflammatory
effects in MS.
A decrease in the genus Prevotella in patients with MS was
noted in several small studies; however, several of these may
have been confounded by treatment with DMT, given the
inclusion of a significant number of treated patients (partic-
ularly interferon [IFN]).6,7 One study found an increase in
Prevotella associated with treatment (pooled group including
IFN and GA), suggesting a possible mechanistic association
for this genus with DMTs.5 In addition, human-derived Pre-
votella histicola suppresses EAE in a CD4+FoxP3+Treg–
dependent fashion.22 In our cohort, we noted no change in
the relative abundance of Prevotella in treated participants
compared with those who were treatment-naive, suggesting
that this genus is less affected by either GA or DMF than by
IFN. Another possible explanation for observed differences in
the effects of DMT on Prevotella in our study compared with
others relates to our use of the V4 hypervariable region as
compared to the use of V3–V5 in the aforementioned studies.
However, previous comparisons of these variations in the
technique have demonstrated relatively consistent results,
making this difference unlikely to fully account for this
discordance.23–25
We noted the genus Sutterella to be 2.4-fold less abundant in
participants treated with GA as compared to those who were
treatment-naive, with no difference in relative abundance with
DMF. An increase in Sutterella in treated compared with
untreated patients withMSwas previously reported; however,
the treatment group included patients treated with either IFN
or GA.5 Suggesting that IFN may in fact be the driving factor,
an additional study has noted an increase in Sutterella in
IFN-treated MS patients.26 In a spontaneous EAE model,
specimens from mice who received transplanted MS fecal
material were noted to be relatively depleted in Sutterella.27
Given that the EAE course worsened in mice transplanted
with fecal material from patients with MS, compared with
those transplanted from a healthy twin, this finding might be
pathologically significant. However, in this experiment, 3 of
the 5 MS twins received treatment with IFN, potentially
confounding interpretation of these results. Further work is
needed to understand whether Sutterella is associated withMS
pathology, whether there are differential effects of DMTs on
the abundance of this genus, and finally whether such po-
tential effects on Sutterella abundance have any clinical
significance.
In our study, the relative abundance of members of the order
Clostridiales (phylum Firmicutes, class Clostridia) was de-
creased. Members of 2 particular Clostridial families, Lach-
nospiraceae and Veillonellaceae, were decreased by both DMF
and GA. Of interest, we previously noted increased relative
abundance of the genus Megasphaera (family Veillonellaceae)
in untreated MS compared with healthy controls.10 DMF
Table 2 Differentially abundant taxa (continued)
Differentially abundant taxa score
Mean relative abundance
FC: log2 (DMF/NA) log10.LDA. p ValueNaive DMF
k__Bacteria.p__Firmicutes.c__Clostridia.o__Clostridiales.f__
[Tissierellaceae].g__Peptoniphilus
3.30E-03 2.07E-04 −4.0 3.3 6.31E-03
k__Bacteria.p__Firmicutes.c__Clostridia.o__Clostridiales.f__
[Tissierellaceae].g__Anaerococcus
2.52E-03 1.84E-04 −3.8 3.2 1.87E-02
k__Bacteria.p__Actinobacteria.c__Actinobacteria.o__
Actinomycetales.f__Corynebacteriaceae.g__Corynebacterium
2.19E-03 2.16E-04 −3.3 3.3 3.07E-02
k__Bacteria.p__Firmicutes.c__Clostridia.o__Clostridiales.f__
Veillonellaceae.g__Megasphaera
1.39E-03 1.49E-04 −3.2 2.8 6.93E-05
k__Bacteria.p__Firmicutes.c__Clostridia.o__Clostridiales.f__
[Tissierellaceae].g__Finegoldia
2.20E-03 3.38E-04 −2.7 3.1 4.28E-02
k__Bacteria.p__Actinobacteria.c__Actinobacteria.o__
Actinomycetales.f__Micrococcaceae.g__Rothia
2.38E-05 4.30E-06 −2.5 2.9 6.91E-04
k__Bacteria.p__Proteobacteria.c__Epsilonproteobacteria.o__
Campylobacterales.f__Campylobacteraceae.g__Campylobacter
4.14E-04 7.59E-05 −2.4 2.9 1.39E-02
k__Bacteria.p__Firmicutes.c__Clostridia.o__Clostridiales.f__
Lachnospiraceae.g__Blautia
4.14E-02 2.92E-02 −0.5 3.8 4.36E-03
k__Bacteria.p__Firmicutes.c__Clostridia.o__Clostridiales.f__
Lachnospiraceae.g__uid_Lachnospiraceae
8.01E-02 6.35E-02 −0.3 3.9 8.18E-03
k__Bacteria.p__Firmicutes.c__Bacilli.o__Bacillales.f__
Planococcaceae.g__uid_Planococcaceae
2.02E-06 0 NA 3.4 3.88E-02
Abbreviations: DMF = dimethyl fumarate; EDSS = Expanded Disability Status Scale; LDA = linear discriminant analysis; NA = not applicable.
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seems to “reverse” this. Clostridial organisms have received
significant attention in demyelinating disorders. An increased
frequency of immunoreactivity to epsilon toxin–producing
Clostridium perfringens type B was observed in patients with
MS, suggesting this organism as contributory to MS pathol-
ogy, given the potentially toxic effects at the blood-brain
barrier.28 A subsequent study demonstrated the ability of
epsilon toxin to destroy oligodendrocytes and induce de-
myelination.29 An overabundance of C perfringens has also
been noted in a small study of patients with neuromyelitis
optica.30 In addition to the described potential effects of
Clostridial members on inflammation, Lachnospiraceae was
demonstrated to impair oligodendrocyte differentiation in
cultured cells and was associated with impaired myelination in
mice.31 Clostridial taxa therefore have potential for pathologic
relevance in MS and the mechanism of action of DMTs both
with respect to inflammation and neurodegeneration/
neuroprotection. In concordance with our results regarding
Figure 3 Cladogram indicating the effect of disease-modifying therapies on the phylogenetic structure of MS patients’
microbiota
Upper: DMF vs Naive. Lower: GA vs
Naive. Only significant taxa (p-value
< 0.05, LDA score >2) identified by
LEfSe were displayed. Differential
abundant taxa are marked by col-
ored shades: red indicates enrich-
ment in the therapy groups (DMF or
GA), and green indicates enrich-
ment in the naive group. Circles
represent phylogenetic levels from
kingdom to genus from inside out.
Each dot represents a taxon and its
diameter is proportional to the tax-
on’s effect size. c = class; DMF = di-
methyl fumarate; f = family; g =
genus; GA = glatiramer acetate; k =
kingdom; LEfSe = linear discriminant
analysis effect size; LDA = linear dis-
criminant analysis; o = order; p =
phylum; uid = unidentified, accord-
ing to the GreenGenes database.
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other Clostridial family members, DMF was noted to inhibit
the log-phase growth of C perfringens in vitro, and inves-
tigators hypothesized that this may be contributory to the
drug’s mechanism of action.32 A decrease in species belonging
to Clostridia clusters was previously found in patients with
MS compared with controls; however, this majority of par-
ticipants in this study were treated with DMTs.7 A decrease in
the relative abundance of Clostridial members could be
common to several MS DMTs.
DMF resulted in a decrease in the relative abundance of many
taxa, with Bacteroidetes members as the only significant in-
crease. The methodology used here to calculate relative
abundance values precludes conclusions about the absolute
numbers of microbes present. However, fumarates have
known antimicrobial properties and in fact DMF was pre-
viously used as an antimicrobial preservative for upholstery.33
Of interest, previous work in EAE suggests that a reduction in
gut bacterial load might be of benefit.3 Compared with mice
who received no antibiotics or intraperitoneal antibiotics,
those who received oral antibiotics before EAE induction
demonstrated reduced EAE severity that correlated to an in-
crease in FoxP3+Treg cells in distal peripheral lymph nodes.
Further, costimulation of harvested lymphocytes from distal
nodes resulted in decreased production of proinflammatory
cytokines such as IFN gamma and increased production of
anti-inflammatory cytokines such as IL-10. Additional studies
are needed to evaluate this potential effect of DMF as its
generalized antimicrobial properties may be a contributing
factor to efficacy in MS.
When considering the ultimate influence of DMT on MS gut
microbiota, the effects of the overall shaping of the microbial
community on downstream functional pathways may bemore
important than effects on individual genera. PICRUSt analysis
may help identify the impact of changes in microbial
Figure 4 Relative abundances of the order Clostridiales and its family members are differentially changed by therapy
Relative abundances of the order Clos-
tridiales (A) and its family members are
differentially changed by therapies (B: Lach-
nospiraceae; C: Veillonellaceae; D: Tissier-
ellaceare). Asterisk (*) indicates significant
change compared with naive as determined
by the LEfSe analysis (see also in table 2). The
inner bisecting line indicates the median. The
lower and upper edges of the box represent
the 25th and the 75th percentiles, re-
spectively. LEfSe = linear discriminant analysis
effect size.
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composition on biological and metabolic pathways and sug-
gest potential mechanisms that link changes in gut microbiota
with therapeutic effects.16 One of the common pathways af-
fected by both GA and DMF was retinol (vitamin A) me-
tabolism. Vitamin A metabolites are known to modulate
specific functional aspects of the immune response, such as
the Th1–Th2-cell balance and the differentiation of Treg and
Th17 cells.34 Retinoic acid also modulates lymphocyte traf-
ficking by enhancing integrin a4b7 expression on lymphocytes
and imprinting them with gut tropism.35 Of interest, dendritic
cells from the gut-associated lymphoid tissue, but not from
the spleen, were able to produce retinoic acid from retinol,
suggesting that vitamin A plays an important role specifically
in the gut-immune system interaction. Another bacterial
pathway affected by both therapies was methane metabolism.
An increased relative abundance of methane-producing bac-
teria and exhaled methane in patients with MS compared with
healthy controls was reported.5 The role of these pathways in
MS pathophysiology and precise effects of therapies will need
to be further explored in future studies.
Our study is still limited by the relatively small sample size and
cross-sectional nature of sample collection, including un-
avoidable imperfect matching of groups with respect to age,
sex, and disease duration. Also, although recruitment at 2
separate locations is a merit, particularly because careful at-
tention was granted to implement identical methodology and
analyses did not demonstrate community-level differences by
site, it is possible that unmeasured differences in study groups
related to geography confounded our results in some fashion.
Our study results confirm our hypothesis that DMTs for MS
have measurable effects on gut microbiota. Future directions
will include working with a larger cohort with longitudinal
follow-up of individuals who begin new DMTs to assess the
effects more precisely and to evaluate questions regarding
the relationship of gut microbiota to therapy response and
tolerability. Bidirectional relationships have been confirmed
in other disease states36–39 and will need to be investigated in
MS as well. Effects are likely to be particularly important for
orally deliveredmedications. In addition, lessons learned from
these studies may inform our understanding of the patho-
genesis of the disease and lead to the exploration of new
potential treatment targets.
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